Drugs / Doxazosin
last change 4 days ago re-read 2 minutes ago

Doxazosin

Small molecule

Developed for
hypertensive disorder · post-traumatic stress disorder · alcohol-related disorders · benign prostatic hyperplasia · cocaine dependence · essential hypertension · alcohol dependence · allergic rhinitis
+11 more · benign essential hypertension · coronary microvascular disorder · diabetic kidney disease · paraganglioma · pheochromocytoma · prostate disorder · substance-related disorder · urinary tract obstruction · non-familial dilated cardiomyopathy · resistant hypertension · urolithiasis
Investigated by
Baylor College of Medicine · National Institute on Drug Abuse (NIDA) · Brown University · National Heart, Lung, and Blood Institute (NHLBI) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Northern California Institute of Research and Education
+32 more · San Francisco Veterans Affairs Medical Center · United States Department of Defense · VA Office of Research and Development · Viatris Inc. · Boehringer Ingelheim · Buddhist Tzu Chi General Hospital · Charite University, Berlin, Germany · Danish Cardiovascular Research Academy · Danish Heart Foundation · Eisai Inc. · George Washington University · German Federal Ministry of Education and Research · Hospital Authority, Hong Kong · Instituto de Cardiologia do Rio Grande do Sul · Japan Heart Foundation · Medical University of South Carolina · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Novartis · Samsung Medical Center · St George's, University of London · The University of Texas Health Science Center, Houston · University Hospital, Basel, Switzerland · University of Aarhus · University of Arkansas · University of California, Los Angeles · University of Campania Luigi Vanvitelli · University of Dundee · University of Minnesota · University of Wisconsin, Madison · VIVUS LLC · Yale University · Yokohama City University Medical Center

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) CARDURA 1990-11-02 fda.gov

Trials 33 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01437046 Nov 2011 → Aug 2013 alcohol dependence, anxiety Brown University Completed No outcome recorded
Phase 15 trials
Phase 1 NCT03398252 May 2022 → Oct 2023 alcohol-related disorders The University of Texas Health Science Center, Houston Withdrawn No outcome recorded
Phase 1 NCT01386177 Jul 2011 → Jan 2012 amphetamine abuse, mood disorder University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 1 NCT01100021 Feb → Mar 2010 erectile dysfunction VIVUS LLC Completed No outcome recorded
Phase 1 NCT00880997 Sep 2009 → Apr 2011 cocaine dependence Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT02266537 Nov 2005 → Feb 2006 Boehringer Ingelheim Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01371851 Jun 2011 → May 2014 substance-related disorder University of Arkansas Completed No outcome recorded
Phase 29 trials
Phase 2 NCT05360953 Jun 2022 → Aug 2025 post-traumatic stress disorder Charite University, Berlin, Germany Suspended No outcome recorded
Phase 2 NCT04135846 Dec 2019 → Aug 2026 overdue alcohol-related disorders Brown University Recruiting No outcome recorded
Phase 2 NCT03339258 Apr 2018 → Jun 2024 post-traumatic stress disorder San Francisco Veterans Affairs Medical Center Unknown No outcome recorded
Phase 2 NCT02989493 Apr 2017 → Mar 2020 alcohol dependence University of Wisconsin, Madison Completed No outcome recorded
Phase 2 NCT02500602 Jun 2016 → Dec 2019 alcohol-related disorders, post-traumatic stress disorder VA Office of Research and Development Completed No outcome recorded
Phase 2 NCT01953432 Apr 2014 → Sep 2017 cocaine dependence VA Office of Research and Development Completed No outcome recorded
Phase 2 NCT01730846 Feb 2013 → Nov 2016 Yale University Completed No outcome recorded
Phase 2 NCT01145183 Mar 2010 → Sep 2015 cocaine dependence Baylor College of Medicine Completed No outcome recorded
Phase 2 NCT00000522 Aug 1985 → May 1994 heart disorder, hypertensive disorder University of Minnesota Completed No outcome recorded
Phase 33 trials
Phase 3 NCT03176693 May 2017 → Jan 2020 paraganglioma, pheochromocytoma University of California, Los Angeles Completed No outcome recorded
Phase 3 NCT00021814 Dec 1995 → Nov 2001 benign prostatic hyperplasia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed No outcome recorded
Phase 3 NCT00000542 Aug 1993 → Mar 2002 coronary artery disorder, diabetes mellitus, heart failure, hyperlipidemia +3 National Heart, Lung, and Blood Institute (NHLBI) Completed No outcome recorded
Phase 49 trials
Phase 4 NCT01959022 Oct 2013 → Jun 2016 post-traumatic stress disorder San Francisco Veterans Affairs Medical Center Completed No outcome recorded
Phase 4 NCT01946035 Sep 2013 → Jun 2015 allergic rhinitis University of Dundee Completed No outcome recorded
Phase 4 NCT01661621 Aug 2012 → Aug 2013 urinary tract obstruction Buddhist Tzu Chi General Hospital Completed No outcome recorded
Phase 4 NCT00130156 Oct 2005 → Sep 2008 benign essential hypertension Eisai Inc. Completed No outcome recorded
Phase 4 NCT00535925 Oct 2005 → Dec 2011 diabetic kidney disease University of Campania Luigi Vanvitelli Completed No outcome recorded
Phase 4 NCT00295555 Jan 2004 → Apr 2007 diabetes mellitus, essential hypertension, kidney failure Yokohama City University Medical Center Completed No outcome recorded
Phase 4 NCT00648323 Nov 2003 → Jan 2005 prostate disorder Viatris Inc. Completed No outcome recorded
Phase 4 NCT00285519 Aug 2003 → Aug 2005 hypertensive disorder Japan Heart Foundation Completed No outcome recorded
Phase 4 NCT00646841 Feb 2003 → Feb 2004 essential hypertension Viatris Inc. Completed No outcome recorded
Phase not applicable5 trials
NCT04371757 Apr → Dec 2020 autonomic nervous system disorder, hypertensive disorder Instituto de Cardiologia do Rio Grande do Sul Unknown No outcome recorded
NCT00730418 Jan 2007 → Mar 2010 benign prostatic hyperplasia Samsung Medical Center Completed No outcome recorded
NCT00424801 Jan 2007 → Dec 2008 coronary microvascular disorder, essential hypertension University of Aarhus Terminated No outcome recorded
NCT00563485 Oct 2005 → Nov 2006 benign prostatic hyperplasia Hospital Authority, Hong Kong Terminated No outcome recorded
NCT00141596 Jul 2003 → Oct 2006 hypertensive disorder St George's, University of London Terminated No outcome recorded
Also used as a comparator or background therapy in 17 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT02538744 Comparator Aug 2015 → Aug 2018 cocaine dependence Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT02308202 Comparator Jan 2012 → Jun 2014 post-traumatic stress disorder Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT02785393 Comparator Mar 2011 → Mar 2016 substance-related disorder Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT01062945 Comparator Jan 2010 → Jan 2011 cocaine abuse, cocaine dependence Baylor College of Medicine Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01678313 Background Aug 2012 → Aug 2013 benign prostatic hyperplasia Buddhist Tzu Chi General Hospital Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02563405 Comparator Sep 2015 → Oct 2017 hypertensive disorder First Affiliated Hospital of Harbin Medical University Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT00713739 Comparator Jan 2008 → Dec 2010 urolithiasis United States Naval Medical Center, San Diego Unknown No outcome recorded
Phase 48 trials
Phase 4 NCT01379898 Comparator Dec 2011 → Jan 2018 pheochromocytoma University Medical Center Groningen Completed No outcome recorded
Phase 4 NCT02901977 Comparator Mar 2011 → Feb 2015 hypertensive disorder Karolinska Institutet Completed No outcome recorded
Phase 4 NCT02369081 Comparator May 2009 → Jul 2015 resistant hypertension University of Cambridge Unknown No outcome recorded
Phase 4 NCT00922506 Background May 2009 → May 2014 benign prostatic hyperplasia, overactive bladder Samsung Medical Center Completed No outcome recorded
Phase 4 NCT00687388 Comparator May 2008 → Mar 2012 benign prostatic hyperplasia Samsung Medical Center Withdrawn No outcome recorded
Phase not applicable2 trials
NCT05094947 Background Aug 2021 → Mar 2022 benign prostatic hyperplasia Moscow State University of Medicine and Dentistry Unknown No outcome recorded
NCT00684489 Comparator Sep 2003 → Mar 2005 essential hypertension Medical University of South Carolina Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2000-10-22 Teva Branded Pharmaceutical Products R&D, Inc. Teva Received Final Approval for Doxazosin Mesylate tevapharm.com

Evidence & citations 30 cited values

Every value below carries the sentence it was read from. 53 sources stand behind the page.

FieldValueCited text
Known as Doxazosin “Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)” NCT00687388
50

Doxazosin produced clinically significant decreases in standing and supine blood pressures over a period of 1 year.” PMID 2884855 May 1987

“nisoldipine, doxazosin, prazosin, terazosin, clonidine” NCT00684489

“tamsulosin, alfuzosin, doxazosin, silodosin” NCT05094947

doxazosin GITS (Cardura XL) 4 mg b.d.” NCT00141596

DoxazosinNCT04371757

NCT02563405

NCT01661621

NCT00730418

NCT01062945

NCT00648323

NCT00295542

NCT01145183

NCT02989493

NCT00424801

NCT02538744

NCT00880997

NCT02785393

NCT03398252

NCT00000522

NCT01386177

NCT04135846

NCT00021814

NCT01678313

NCT00922506

NCT00295555

NCT00130156

NCT00661895

NCT05360953

NCT01953432

NCT00535925

NCT00000542

NCT01959022

NCT03176693

NCT00713739

NCT02266537

NCT01798992

NCT00563485

NCT02500602

NCT00646841

NCT02308202

NCT01371851

NCT01437046

NCT03339258

NCT01379898

NCT01730846

NCT02901977

NCT00285519

NCT01946035

NCT01100021

NCT02369081

Known as Alfadil ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as C02CA04 ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Cardozin xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Cardura “oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together” NCT00021814
Known as Cardura (Doxazosin Mesylate) Cardura (Doxazosin Mesylate)NCT00880997
2

Cardura (Doxazosin Mesylate)NCT01953432

Cardura (Doxazosin Mesylate)NCT01145183

Known as Cardura XL “doxazosin GITS (Cardura XL) 4 mg b.d.” NCT00141596
1

“Doxazosin GITS (Cardura XL)” NCT00563485

Known as Cascor ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Colixil xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxaben XL “Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.” NCT00130156
Known as Doxadura ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxazosin (as mesilate) ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxazosin GITS Doxazosin GITS (Cardura XL)” NCT00563485
Known as Doxazosin mesilate ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as DOXAZOSIN MESYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxazosin methanesulfonate ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as doxazosin XL “The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder.” NCT02308202
Known as Doxazosina ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxazosine ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Doxzogen xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Larbex xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as NSC-759284 ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Oxandosin xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Raporsin xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707
Known as Slocinx xl ChEMBL registry synonym — accepted as the source's own label CHEMBL707